We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

176 hedge funds and large institutions have $2.44B invested in Celldex Therapeutics in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 68 increasing their positions, 55 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more call options, than puts

Call options by funds: $61.1M | Put options by funds: $35.8M

24% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 55

2.74% more ownership

Funds ownership: 105.59% → 108.33% (+2.7%)

3% less funds holding

Funds holding: 182 → 176 (-6)

5% less capital invested

Capital invested by funds: $2.58B → $2.44B (-$135M)

21% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 28

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
176
Holders Change
-6
Holders Change %
-3.3%
% of All Funds
2.53%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
22
Increased
68
Reduced
55
Closed
28
Calls
$61.1M
Puts
$35.8M
Net Calls
+$25.3M
Net Calls Change
+$39M

Top Buyers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$66.1M
2
WP
Woodline Partners
California
+$60.3M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$44.5M
4
Goldman Sachs
Goldman Sachs
New York
+$36.6M
5
LGM
Logos Global Management
California
+$34.3M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$68.8M
2
Marshall Wace
Marshall Wace
United Kingdom
-$42M
3
SI
Sofinnova Investments
California
-$20.3M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$14.1M
5
PCH
Polar Capital Holdings
United Kingdom
-$13.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
176
Candriam SCA
Luxembourg
– -$11.8M -317,509 Closed
LCM
177
Laurion Capital Management
New York
– -$10.8M -290,850 Closed
N
178
Natixis
France
– -$6.13M -165,500 Closed
SC
179
Stempoint Capital
New York
– -$5.35M -144,467 Closed
Qube Research & Technologies (QRT)
180
Qube Research & Technologies (QRT)
United Kingdom
– -$4.64M -125,506 Closed
SSA
181
Schonfeld Strategic Advisors
New York
– -$4.43M -119,629 Closed
AI
182
Atom Investors
Texas
– -$1.93M -52,164 Closed
Walleye Capital
183
Walleye Capital
New York
– -$1.86M -50,183 Closed
Renaissance Technologies
184
Renaissance Technologies
New York
– -$1.58M -42,788 Closed
ECM
185
ExodusPoint Capital Management
New York
– -$1.41M -38,150 Closed
TI
186
Trexquant Investment
Connecticut
– -$448K -12,092 Closed
Principal Financial Group
187
Principal Financial Group
Iowa
– -$391K -10,572 Closed
HT
188
Headlands Technologies
Illinois
– -$340K -9,182 Closed
Group One Trading
189
Group One Trading
Illinois
– -$334K -8,757 Closed
Simplex Trading
190
Simplex Trading
Illinois
– -$328K -8,600 Closed
PFS
191
Prospera Financial Services
Texas
– -$287K -7,754 Closed
EFM
192
E Fund Management
China
– -$269K -7,258 Closed
SO
193
STRS Ohio
Ohio
– -$244K -6,600 Closed
CC
194
Corton Capital
Ontario, Canada
– -$229K -6,179 Closed
A
195
Allianz
Germany
– -$51.8K -1,400 Closed
CFM
196
Catalyst Funds Management
Australia
– -$33.3K -900 Closed
Pacer Advisors
197
Pacer Advisors
Pennsylvania
– -$25.2K -680 Closed
KFS
198
Kelly Financial Services
Massachusetts
– -$1.7K -46 Closed
RWMG
199
Redwood Wealth Management Group
New Jersey
– -$1.22K -33 Closed
HFM
200
Hartford Financial Management
Connecticut
– -$667 -18 Closed
5 6 7
8
9

CLDX Hedge Fund Activity: Q3 2024 in Review

176 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2024, worth a combined $2.44B — down 5.2% from $2.58B a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of CLDX and 22 opened new positions — a net loss of 6 holders — while 55 trimmed existing stakes and 68 added.

The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $66.1M. The largest seller was Fidelity Investments, cutting an estimated $68.8M.

  • 176 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2024, down from 182 in Q2 2024.
  • Funds reported $2.44B of Celldex Therapeutics stock for Q3 2024, down 5.2% quarter-over-quarter.
  • 22 funds opened new Celldex Therapeutics positions in Q3 2024 and 28 closed out, a net change of -6 holders.
  • The largest Celldex Therapeutics buyer in Q3 2024 was T. Rowe Price Investment Management, an estimated $66.1M added.
  • The largest Celldex Therapeutics seller in Q3 2024 was Fidelity Investments, an estimated $68.8M sold.

Based on aggregated 13F filings for Q3 2024.